Publications in collaboration with researchers from Christie Hospital NHS Foundation Trust (6)

2022

  1. Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours (Nature Communications, (2020), 11, 1, (737), 10.1038/s41467-019-14052-x)

    Nature Communications

2020

  1. Divergent mutational processes distinguish hypoxic and normoxic tumours

    Nature Communications, Vol. 11, Núm. 1

2017

  1. Gefitinib and EGFR gene copy number aberrations in esophageal cancer

    Journal of Clinical Oncology, Vol. 35, Núm. 20, pp. 2279-2287

2014

  1. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): A phase 3, multicentre, double-blind, placebo-controlled randomised trial

    The Lancet Oncology, Vol. 15, Núm. 8, pp. 894-904

  2. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 8, pp. 829-840

  3. Phase II trial of cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study

    Translational Oncology, Vol. 7, Núm. 1, pp. 55-64